Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind and prospective trial meant to evaluate the use of Glibenclamide
on acute aneurysmatic subarachnoid hemorrhage. Patients will allocated randomly in two
groups, one for 05 mg daily intake of glibenclamide for 21 days and another for control with
placebo. General clinical data and late cognitive status will be accessed in both groups.